Lexeo Therapeutics Inc

Lexeo COO’s Tax‑Cover Sale Highlights Insider’s Tightrope Between Growth Confidence and Personal Liquidity Amid Volatile Biotech Market.

Insider trading insights: Lexeo COO’s February sale reflects tax coverage amid volatile biotech stocks—what this means for investors and future prospects.

Lexeo Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

20/02/2026, 23:33

3 minutes to read

Lexeo CEO Lands $1.9 Million in RSU Grants—A Bold Bet on Gene‑Therapy Success Despite Stock Slide

Lexeo Therapeutics’ CEO buys 161,665 shares and 646,665 options – a strong leadership signal that hinges on upcoming clinical milestones and potential partnerships.

Lexeo Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

06/02/2026, 23:18

4 minutes to read